 Immunic Incs NASDAQ: IMUX lead candidate, IMU-838, has an attractive safety profile and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. The Immunic Analyst: Gobind Singh initiated coverage of Immunic with a Market Outperform rating and a price target of 55. 